A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 110
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : FACT-P
Long Form : Functional Assessment of Cancer Therapy-Prostate
No. Year Title Co-occurring Abbreviation
2021 An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. HRQL, mCRPC, TS
2021 Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. ADT, CI, HR, HRQoL, MFS, nmCRPC, OS, PCS
2021 Effect of Combining Traditional Chinese Medicine with Hormonal Therapy on Quality of Life and Tumor Markers of Prostate Cancer Patients. fPSA, TCM, tPSA
2021 Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. EPIC, FACIT-F, FACT-G, QoL
2021 Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. ADT, HRQoL, nmCRPC
2021 Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. BPI-SF, HRQoL, IOCR, mCRPC, PAB, Ra-223, TPP, TTFD
2021 Knowledge and Attitudes Regarding Surgical Castration in Men Receiving Androgen Deprivation Therapy for Metastatic Prostate Cancer and Their Relationship to Health-Related Quality of Life. ADT, HRQoL, mCaP
2021 Nutritional Status and Health-Related Quality of Life in Men with Advanced Castrate-Resistant Prostate Cancer. mCRPC, NS, WN
2021 Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. HRQL, mCRPC, PROSELICA, PSA, TS
10  2021 Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. IPSS, PCa
11  2021 Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. AAP, CI, HRQoL, mCRPC, PRISMA, PROs, RCTs
12  2020 Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. ADT, CI, HR, MD, RCT, RR
13  2020 Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. ADT, HRQoL, mHSPC, PROs, QLQ-PR25, rPFS
14  2020 Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. EQ-5D, HRQoL, PCa, PRISMA
15  2020 Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. AEs, BPI-SF, CRPC, Ra 223
16  2020 Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. BPI-SF, CARD, ECOG, EQ-5D-5L, HR, PROs
17  2020 Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. BFI, BPI-SF, CHS-PCa, mCRPC, MoCA, PROs, PSA, SD
18  2020 [Family-centered psychological support helps improve illness cognition and quality of life in patients with advanced prostate cancer]. FCPS, ICQ, PCa
19  2019 Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. AA, CAB, cT2, HT, LHRHa, PCa, PSA, pT3, QoL, RP
20  2019 Ambulatory Robot-Assisted Laparoscopic Prostatectomy: Is It Ready for Prime Time? A Quality of Life Analysis. CT, EWB, FACT-G, NDD, PIS, PSS, QoL, RALP
21  2019 Does trunk muscle training with an oscillating rod improve urinary incontinence after radical prostatectomy? A prospective randomized controlled trial. CG, HRQL, IG
22  2019 Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol. AAP, HRQoL, mCRPC
23  2019 Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. CRPC, DM, EQ-5D-5L, EQ-VAS, GLM, HRQoL, LP, PC
24  2019 Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. ADT, BFI, BPI-SF, EQ-5D-5L, HRQoL, TITAN
25  2019 Health-Related Quality of Life and Its Associated Factors in Prostate Cancer Patients Who Receive Androgen Deprivation Therapy. ADT, HRQoL
26  2019 Home-based 'exergaming' was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial. 6MWT, ADT, FACT-F, LEP, QoL
27  2019 Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. ADT, AEs, HRQoL, MAIC, nmCRPC, ORs
28  2019 Meaningful differences and validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. NFPSI-17
29  2019 Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. BPI-SF, HR
30  2019 Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. LAPC, QoL
31  2019 Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. CRPC, QoL
32  2018 A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. HRQoL, PC, QALYs
33  2018 A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. IPSS
34  2018 An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). AE, CAPRISTANA, HRQoL, mCRPC, OS, PFS, TTF
35  2018 Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. HRQoL, ICIQ-MLUTS, LUTS, RARP, SD
36  2018 Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. HRQoL
37  2018 Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. HRQoL, MMRM, MoCA, PHQ-9
38  2018 Investigating the relationships between quality of life, fatigue and leisure time physical activity in prostate cancer patients. FACIT-F, GLTEQ, PCa
39  2018 Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. ADT, BFI, BPI-SF, ECOG, HR, HRQoL, PROs
40  2018 Perceptions of masculinity and body image in men with prostate cancer: the role of exercise. BIS, GLTEQ, MSES, PAQ
41  2018 Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. ADT, QoL
42  2018 Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions. PCa, SDM
43  2018 Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. mCRPC, QoL, TOI
44  2018 [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. CRPC, PSA
45  2017 A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. BPI, EQ-5D, OS, rPFS, TEAE
46  2017 Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases. BPI-SF, CRPC, ES, HRQoL, HRU, IRR, SSEs
47  2017 Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy. ADT, FACIT-F, HADS, HRQoL
48  2017 Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. mCRPC, OT, QoL
49  2017 Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. CI, HRQoL, mCRPC, SREs
50  2017 The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. CIs, HRQoL, HRs, mCRPC, MID, OS, PREVAIL, rPFS
51  2016 "What if…": decisional regret in patients who discontinued active surveillance. AS
52  2016 Erratum to: The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. SF-12v2
53  2016 Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men. GB, HRQoL, PCa
54  2016 Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. EQ-5D, HRQoL, mCRPC
55  2016 Oncology Section EDGE Task Force on Prostate Cancer: A Systematic Review of Outcome Measures for Health-Related Quality of Life. EPIC, FACT-G, HRQoL, SF, UCLA-PCI
56  2016 Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. CI, CRPC, EQ-5D, OR, QoL, radium-223, SOC
57  2016 Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. HRQoL, mCRPC, PCS, PMM, PROs, TOI
58  2016 The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer. SF-12v2
59  2015 Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. BPI-SF, HR, HRQoL
60  2015 Health-related quality of life of Chinese patients with prostate cancer in comparison to general population and other cancer populations. HRQoL, SF-12 v2
61  2015 Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. EPIC, NCCN, PROs, QoL, SF, UCLA-PCI
62  2015 Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer. ---
63  2015 Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. CECs, CI, CRPC, PPI, PSA, TTPP, TTTF
64  2014 A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. BAP, BTM, CRPC, PFS, PPI, VEGFR
65  2014 Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. CDF, mCRPC, PMM
66  2014 Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. EQ-5D, HRQoL, mCRPC, OLS, SD
67  2014 Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer. HRQoL
68  2013 A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. BPI, CI, CRPC, OS, PFS, PSA
69  2013 A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. PC, PCI, QoL
70  2013 Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. BPI-SF, HR, HRQoL
71  2013 Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. HRQoL, mCRPC
72  2013 Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. ADT, CI, FACT-F, QoL
73  2013 Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials. BPI, PPI
74  2013 Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy. EBRT, HDR, TOI
75  2011 Racial differences in well-being and cancer concerns in prostate cancer patients. ---
76  2010 Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. EPIC, PCa, QoL
77  2010 Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). HRPC, HRQoL
78  2010 Prostate cancer: how assessment of QoL can improve delivery of care. DH, QoL
79  2010 Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. BAT, FT, QoL, SHBG, TT
80  2010 The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. ED, HADS
81  2009 Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). CFRT, HR, LENT/SOM, RTOG, UCLA-PCI
82  2008 Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT). EBRT, HDR-BT, HRQoL, QoL
83  2008 Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. AE, BAP, CMCs, FAPSI, KPS, PCS, SEM, TOI, TTP
84  2008 Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. LHRHa, MAB, QoL
85  2008 Measuring the individual quality of life of patients with prostate cancer. QoL, SEIQoL-DW
86  2008 Quality of life before and after prostatectomy as treatment for localized cancer. ---
87  2008 Quality of life in men treated with carbon ion therapy for prostate cancer. C-ion RT, PCS, PWB, QoL, S/FWB, UCLA-PCI
88  2008 Quality of life in patients with prostate cancer: development and application of a hybrid assessment method. QoL
89  2008 [Quality of life among patients with advanced prostate cancer: a survey using functional assessment of cancer therapy-prostate in China]. FACT-G, PCS
90  2007 Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. QoL
91  2007 Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. HRPCa, HRQoL, OLS
92  2007 Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. HRPC, HRQL
93  2006 Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. ---
94  2006 Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. HRPC
95  2006 The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean version. ---
96  2006 Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. AIPC, PSA
97  2005 Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. HRQoL, HRQoL, IPSS, PB, SAQ, SEM
98  2005 Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy. BDI, CRT, ESS, MRT, PCS, PFS, PRT, PWB, QoL
99  2005 Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. HRPC, PSA
100  2004 The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. ---